Humanisation and pre-clinical validation of a therapeutic anti-cancer antibody

  • Janes, Peter (Primary Chief Investigator (PCI))
  • Nikolov, Dimitar (Chief Investigator (CI))
  • Scott, Andrew (Chief Investigator (CI))
  • Sleeman, Mark (Chief Investigator (CI))

Project: Research

StatusFinished
Effective start/end date1/01/15 → 31/12/17

Funding

  • National Health & Medical Research Council (NHMRC): AUD317,000.00
View all
View less

Related content

Research Output

An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growth

Research output: Contribution to journal › Article › Research › peer-review